• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

实体器官移植受者中新冠病毒再次感染的纵向免疫分析

Longitudinal immune profiling of a SARS-CoV-2 reinfection in a solid organ transplant recipient.

作者信息

Klein Jon, Brito Anderson, Trubin Paul, Lu Peiwen, Wong Patrick, Alpert Tara, Pena-Hernandez Mario, Haynes Winston, Kamath Kathy, Liu Feimei, Vogels Chantal, Fauver Joseph, Lucas Carolina, Oh Ji Eun, Mao Tianyang, Silva Julio, Wyllie Anne, Muenker M Catherine, Casanovas-Massana Arnau, Moore Adam, Petrone Mary, Kalinich Chaney, Cruz Charles Dela, Farhadian Shelli, Ring Aaron, Shon John, Ko Albert, Grubaugh Nathan, Goldman-Israelow Benjamin, Iwasaki Akiko, Azar Marwan

机构信息

Yale University.

Yale.

出版信息

Res Sq. 2021 May 5:rs.3.rs-405958. doi: 10.21203/rs.3.rs-405958/v1.

DOI:10.21203/rs.3.rs-405958/v1
PMID:34013255
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8132249/
Abstract

The underlying immunologic deficiencies enabling SARS-CoV-2 reinfections are currently unknown. Here we describe a renal-transplant recipient who developed recurrent, symptomatic SARS-CoV-2 infection 7 months after primary infection. To elucidate the immunological mechanisms responsible for reinfection, we performed longitudinal profiling of cellular and humoral responses during both primary and recurrent SARS-CoV-2 infection. We found that the patient responded to the primary infection with transient, poor-quality adaptive immune responses that was further compromised by intervening treatment for acute rejection of the renal allograft prior to reinfection. Importantly, we identified the development of neutralizing antibodies and humoral memory responses prior to SARS-CoV-2 reinfection. However, these neutralizing antibodies failed to confer protection against reinfection, suggesting that additional factors are required for efficient prevention of SARS-CoV-2 reinfection. Further, we found no evidence supporting viral evasion of primary adaptive immune responses, suggesting that susceptibility to reinfection may be determined by host factors rather than pathogen adaptation.

摘要

目前尚不清楚导致新冠病毒再次感染的潜在免疫缺陷。在此,我们描述了一名肾移植受者,其在初次感染7个月后出现了复发性、有症状的新冠病毒感染。为了阐明导致再次感染的免疫机制,我们在初次和复发性新冠病毒感染期间对细胞和体液反应进行了纵向分析。我们发现,该患者对初次感染的适应性免疫反应短暂且质量不佳,并且在再次感染前因肾移植急性排斥反应的介入治疗而进一步受损。重要的是,我们在新冠病毒再次感染之前就发现了中和抗体和体液记忆反应的产生。然而,这些中和抗体未能提供针对再次感染的保护作用,这表明有效预防新冠病毒再次感染还需要其他因素。此外,我们没有发现支持病毒逃避初次适应性免疫反应的证据,这表明再次感染的易感性可能由宿主因素而非病原体适应性决定。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b7dc/8132249/55a1aeb02264/nihpp-rs405958v1-f0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b7dc/8132249/34cafd361e90/nihpp-rs405958v1-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b7dc/8132249/00db8330c912/nihpp-rs405958v1-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b7dc/8132249/18f747304d9f/nihpp-rs405958v1-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b7dc/8132249/a6ae03c0a134/nihpp-rs405958v1-f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b7dc/8132249/55a1aeb02264/nihpp-rs405958v1-f0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b7dc/8132249/34cafd361e90/nihpp-rs405958v1-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b7dc/8132249/00db8330c912/nihpp-rs405958v1-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b7dc/8132249/18f747304d9f/nihpp-rs405958v1-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b7dc/8132249/a6ae03c0a134/nihpp-rs405958v1-f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b7dc/8132249/55a1aeb02264/nihpp-rs405958v1-f0005.jpg

相似文献

1
Longitudinal immune profiling of a SARS-CoV-2 reinfection in a solid organ transplant recipient.实体器官移植受者中新冠病毒再次感染的纵向免疫分析
Res Sq. 2021 May 5:rs.3.rs-405958. doi: 10.21203/rs.3.rs-405958/v1.
2
Case Study: Longitudinal immune profiling of a SARS-CoV-2 reinfection in a solid organ transplant recipient.案例研究:一名实体器官移植受者中新冠病毒再次感染的纵向免疫分析
medRxiv. 2021 Mar 26:2021.03.24.21253992. doi: 10.1101/2021.03.24.21253992.
3
Longitudinal Immune Profiling of a Severe Acute Respiratory Syndrome Coronavirus 2 Reinfection in a Solid Organ Transplant Recipient.器官移植受者严重急性呼吸综合征冠状病毒 2 再感染的纵向免疫分析。
J Infect Dis. 2022 Feb 1;225(3):374-384. doi: 10.1093/infdis/jiab553.
4
Reinfection with SARS-CoV-2 in solid-organ transplant recipients: Incidence density and convalescent immunity prior to reinfection.实体器官移植受者中 SARS-CoV-2 的再感染:再感染前的发病率密度和恢复期免疫。
Transpl Infect Dis. 2022 Jun;24(3):e13827. doi: 10.1111/tid.13827. Epub 2022 Apr 6.
5
Symptomatic Severe Acute Respiratory Syndrome Coronavirus 2 Reinfection of a Healthcare Worker in a Belgian Nosocomial Outbreak Despite Primary Neutralizing Antibody Response.比利时医院感染暴发中,一名医护人员出现有症状的严重急性呼吸综合征冠状病毒 2 再感染,尽管存在初级中和抗体反应。
Clin Infect Dis. 2021 Nov 2;73(9):e2985-e2991. doi: 10.1093/cid/ciaa1850.
6
Robust humoral and cellular immune responses and low risk for reinfection at least 8 months following asymptomatic to mild COVID-19.在无症状至轻症 COVID-19 感染至少 8 个月后,仍能产生强大的体液和细胞免疫反应,并降低再次感染的风险。
J Intern Med. 2022 Jan;291(1):72-80. doi: 10.1111/joim.13387. Epub 2021 Sep 27.
7
Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection.SARS-CoV-2 的持久免疫控制和预防再感染的前景。
Nat Rev Immunol. 2021 Jun;21(6):395-404. doi: 10.1038/s41577-021-00550-x. Epub 2021 Apr 29.
8
Protection against reinfection with D614- or G614-SARS-CoV-2 isolates in golden Syrian hamster.金黄地鼠对 D614 或 G614 刺突蛋白 SARS-CoV-2 分离株再感染的保护作用。
Emerg Microbes Infect. 2021 Dec;10(1):797-809. doi: 10.1080/22221751.2021.1913974.
9
Reinfection with new variants of SARS-CoV-2 after natural infection: a prospective observational cohort in 13 care homes in England.自然感染后新型 SARS-CoV-2 变体再感染:英国 13 家养老院的前瞻性观察队列研究。
Lancet Healthy Longev. 2021 Dec;2(12):e811-e819. doi: 10.1016/S2666-7568(21)00253-1. Epub 2021 Dec 1.
10
Cellular and humoral responses after second and third SARS-CoV-2 vaccinations in patients with autoimmune diseases treated with rituximab: specific T cell immunity remains longer and plays a protective role against SARS-CoV-2 reinfections.在接受利妥昔单抗治疗的自身免疫性疾病患者中,第二次和第三次接种 SARS-CoV-2 疫苗后的细胞和体液反应:特异性 T 细胞免疫持续时间更长,并对 SARS-CoV-2 再感染起到保护作用。
Front Immunol. 2023 Apr 27;14:1146841. doi: 10.3389/fimmu.2023.1146841. eCollection 2023.

本文引用的文献

1
Protein-Based Immunome Wide Association Studies (PIWAS) for the Discovery of Significant Disease-Associated Antigens.基于蛋白质的免疫组学全基因组关联研究(PIWAS)在发现重要疾病相关抗原中的应用。
Front Immunol. 2021 Apr 27;12:625311. doi: 10.3389/fimmu.2021.625311. eCollection 2021.
2
Immunogenicity of a Single Dose of SARS-CoV-2 Messenger RNA Vaccine in Solid Organ Transplant Recipients.mRNA 疫苗在实体器官移植受者中的单剂免疫原性。
JAMA. 2021 May 4;325(17):1784-1786. doi: 10.1001/jama.2021.4385.
3
Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection.
对感染后长达 8 个月的 SARS-CoV-2 进行免疫记忆评估。
Science. 2021 Feb 5;371(6529). doi: 10.1126/science.abf4063. Epub 2021 Jan 6.
4
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine.mRNA-1273 新型冠状病毒疫苗的有效性和安全性。
N Engl J Med. 2021 Feb 4;384(5):403-416. doi: 10.1056/NEJMoa2035389. Epub 2020 Dec 30.
5
Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers.医护人员中抗SARS-CoV-2抗体状态及感染发生率
N Engl J Med. 2021 Feb 11;384(6):533-540. doi: 10.1056/NEJMoa2034545. Epub 2020 Dec 23.
6
B cell depletion therapies in autoimmune disease: advances and mechanistic insights.自身免疫性疾病中的 B 细胞耗竭疗法:进展与机制见解。
Nat Rev Drug Discov. 2021 Mar;20(3):179-199. doi: 10.1038/s41573-020-00092-2. Epub 2020 Dec 15.
7
Long-term SARS-CoV-2 RNA shedding and its temporal association to IgG seropositivity.新型冠状病毒长期RNA脱落及其与IgG血清阳性的时间关联。
Cell Death Discov. 2020 Dec 2;6(1):138. doi: 10.1038/s41420-020-00375-y.
8
Correlates of protection against SARS-CoV-2 in rhesus macaques.恒河猴中 SARS-CoV-2 保护作用的相关因素。
Nature. 2021 Feb;590(7847):630-634. doi: 10.1038/s41586-020-03041-6. Epub 2020 Dec 4.
9
Shedding of Viable SARS-CoV-2 after Immunosuppressive Therapy for Cancer.癌症免疫抑制治疗后活的严重急性呼吸综合征冠状病毒2的脱落
N Engl J Med. 2020 Dec 24;383(26):2586-2588. doi: 10.1056/NEJMc2031670. Epub 2020 Dec 1.
10
Case Study: Prolonged Infectious SARS-CoV-2 Shedding from an Asymptomatic Immunocompromised Individual with Cancer.病例研究:一名患有癌症的无症状免疫功能低下个体长期感染性严重急性呼吸综合征冠状病毒2(SARS-CoV-2)脱落。
Cell. 2020 Dec 23;183(7):1901-1912.e9. doi: 10.1016/j.cell.2020.10.049. Epub 2020 Nov 4.